CareDx (CDNA) Tops Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
CareDx, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results
March 17, 2015 4:05 PM EDTBRISBANE, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today reported financial results for the three months and full year ended December 31, 2014.
Recent Financial Highlights:
For the full year 2014, revenues were $27.3 million versus $22.1 million in 2013, an increase of 24%. Revenue from AlloMap, the Company's flagship molecular diagnostic surveillance solution, grew to $25.8 million in 2014 compared to $21.7 million in 2013, an increase of 19%. Net income for... MoreCareDx, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results
March 17, 2015 4:05 PM EDTBRISBANE, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today reported financial results for the three months and full year ended December 31, 2014.
Recent Financial Highlights:
For the full year 2014, revenues were $27.3 million versus $22.1 million in 2013, an increase of 24%. Revenue from AlloMap, the Company's flagship molecular diagnostic surveillance solution, grew to $25.8 million in 2014 compared to $21.7 million in 2013, an increase of 19%. Net income for... More